GE HealthCare
GEHC
$61.58
+0.11%
GE HealthCare Technologies Inc. is a leading global medical technology firm operating in the healthcare sector, with a core business focused on imaging and ultrasound equipment, advanced visualization solutions, patient care solutions, and pharmaceutical diagnostics. The company is a market leader in medical imaging, distinguished by its strong brand, extensive installed base, and a business model where approximately half of its revenue is recurring from services, consumables, and digital solutions. The current investor narrative is dominated by a significant earnings guidance cut and cost inflation pressures, as evidenced by a sharp stock decline following the company's announcement of $250 million in cost inflation that its long sales cycles make difficult to offset immediately, raising concerns about near-term profitability and margin resilience.…
GEHC
GE HealthCare
$61.58
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating: Hold. The core thesis is that while GEHC's fundamentals have deteriorated sharply, creating a value opportunity, the near-term execution risks and negative momentum warrant caution until evidence of a turnaround emerges.
Supporting evidence includes a forward P/E of 11.29x that prices in a significant earnings rebound, a strong recurring revenue base (~50% of sales) supporting $1.5B in TTM FCF, and analyst maintained Buy ratings suggesting long-term value. However, this is counterbalanced by a -12.13% YoY revenue decline, a 960 bps collapse in net margin, and severe technical damage with the stock down 24.37% in 3 months.
The thesis would upgrade to a Buy if the company demonstrates sequential margin improvement in the next quarter, holds revenue above consensus estimates of $25.69B, and the stock holds firmly above the $58.75 support. It would downgrade to a Sell if Q4 margin compression proves not to be a one-off, revenue decline accelerates further, or the stock breaks below $58.75. Currently, the stock appears fairly valued relative to its heightened near-term risks but undervalued if a multi-year recovery is assumed.
Sign up to view all
GEHC 12-Month Price Forecast
The outlook is clouded with high near-term uncertainty but framed by a compelling risk/reward at current prices. The base case of a slow, volatile recovery is most probable, given the long sales cycles and embedded nature of cost inflation. The stance would upgrade to bullish on confirmation of margin stabilization in the next 1-2 quarters, evidenced by gross margin holding above 54%. It would turn bearish if the next earnings report shows further deterioration in either revenue or operating margin, invalidating the recovery narrative embedded in the forward P/E.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $80.05 and implied upside of +30.0% versus the current price.
Average Target
$80.05
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$49 - $80
Analyst target range
The stock is covered by 9 analysts, and recent institutional ratings show a mix of Buy/Overweight and Hold/Equal Weight recommendations, with firms like BTIG, Wells Fargo, and Stifel maintaining Buy ratings even after the guidance cut, suggesting some maintained long-term conviction. The average analyst revenue estimate for the upcoming period is $25.69 billion, with a tight range between $25.38 billion and $25.93 billion, indicating strong consensus on the top-line outlook, though the wide target price spread typical of analyst coverage would signal differing views on the earnings recovery path and margin assumptions post-guidance reduction.
Bulls vs Bears: GEHC Investment Factors
The bear case currently holds stronger evidence, driven by the severe, quantifiable deterioration in profitability and revenue, which has triggered a technical breakdown. However, the bull case is supported by a valuation that now prices in significant distress and a resilient recurring revenue model. The single most important tension in the investment debate is whether GEHC's operational challenges are a transient, inflation-driven margin squeeze or a sign of deeper competitive or structural issues. The resolution of this tension, visible in upcoming quarterly margins and management's ability to execute on cost controls, will determine if the stock is a deep-value turnaround or a value trap.
Bullish
- Deeply Oversold, Near 52-Week Low: The stock trades at $60.76, just 3.4% above its 52-week low of $58.75, positioning it at a mere 2.2% of its 52-week range. This extreme technical oversold condition suggests the market has priced in severe pessimism, creating a potential value opportunity if the company stabilizes.
- Strong Recurring Revenue Base: Approximately 50% of GEHC's revenue is recurring from services, consumables, and digital solutions. This provides a stable cash flow foundation, evidenced by $1.5 billion in TTM free cash flow, which can help weather cyclical equipment sales downturns.
- Compelling Forward Valuation: The forward P/E of 11.29x is a significant discount to the trailing P/E of 17.97x, indicating the market expects an earnings recovery. This valuation is at the low end of the stock's historical P/E range, suggesting limited downside if guidance is met.
- Analyst Long-Term Conviction: Despite the sharp guidance cut, several major firms (BTIG, Wells Fargo, Stifel) maintain Buy ratings. This suggests institutional belief in the company's long-term market leadership and its ability to manage through near-term cost inflation.
Bearish
- Severe Profitability Contraction: Q4 2025 net income collapsed to $184 million (3.94% margin) from $720 million (13.54% margin) a year ago. Gross margin compressed 310 bps to 54.30%, directly reflecting the $250 million in unabsorbed cost inflation cited in guidance.
- Accelerating Revenue Decline: Q4 2025 revenue fell 12.13% YoY to $4.67 billion, a sequential drop from $5.14 billion in Q3. This negative growth trajectory, coupled with long sales cycles, raises concerns about the company's ability to offset cost pressures through volume.
- Catastrophic Technical Breakdown: The stock is in a severe downtrend, down 24.37% over 3 months and 17.34% over 1 month, massively underperforming the S&P 500 by -22.94% in one month. This momentum indicates a capitulation phase and broken investor confidence.
- High Execution Risk on Guidance: The company explicitly stated its long sales cycles make it difficult to immediately offset $250 million in cost inflation. This creates high uncertainty around the forward P/E of 11.29x, which is entirely dependent on a successful margin recovery that management has flagged as challenging.
GEHC Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -16.66% and a 3-month decline of -24.37%, significantly underperforming the broader market. Currently trading at $60.76, the price sits just 3.4% above its 52-week low of $58.75, positioning it at a mere 2.2% of its 52-week range ($58.75 to $89.77), which signals deep oversold conditions and potential value opportunity but also reflects severe negative momentum and investor pessimism. Recent momentum is decisively negative and accelerating, with a 1-month decline of -17.34% and a 3-month drop of -24.37%, both far worse than the 1-year trend, indicating a severe breakdown and capitulation phase, likely triggered by the recent negative earnings guidance; the stock's relative strength of -22.94% versus the S&P 500 over one month underscores this dramatic underperformance. Key technical support is clearly defined at the 52-week low of $58.75, while resistance is far above at the 52-week high of $89.77; a breakdown below $58.75 would signal a continuation of the bearish trend, whereas a hold could suggest a bottoming process, and with a beta of 0.868, the stock has been less volatile than the market during this decline, which is atypical for such a steep fall and may indicate concentrated selling pressure rather than broad market-driven volatility.
Beta
0.87
0.87x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-15.8%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | -17.5% | +3.3% |
| 3m | -25.8% | +6.9% |
| 6m | -17.6% | +12.4% |
| 1y | -15.8% | +23.4% |
| ytd | -25.6% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
Revenue growth has decelerated and turned negative, with the most recent Q4 2025 revenue of $4.674 billion representing a -12.13% year-over-year decline, and a multi-quarter trend showing a sequential drop from $5.143 billion in Q3 2025, indicating significant top-line pressure likely from macroeconomic and competitive headwinds. Profitability has contracted sharply, with Q4 2025 net income at $184 million (a 3.94% net margin) compared to $720 million (a 13.54% net margin) in Q4 2024, and gross margin compressed to 54.30% from 57.40% a year earlier, reflecting the cited cost inflation and operational challenges that are pressuring earnings. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.96, and while the company generated substantial free cash flow of $1.506 billion over the trailing twelve months, the current ratio of 1.18 indicates adequate short-term liquidity, though the recent guidance cut raises questions about the sustainability of cash generation if margin pressures persist.
Quarterly Revenue
$4.7B
2025-12
Revenue YoY Growth
-0.12%
YoY Comparison
Gross Margin
+0.54%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 17.97x, while the forward P/E is significantly lower at 11.29x, indicating the market is pricing in a substantial earnings recovery, though the wide gap also reflects uncertainty and the recent guidance cut. Compared to sector averages, GEHC's trailing P/E of 17.97x and forward P/E of 11.29x are not directly comparable without a provided industry average, but its Price/Sales ratio of 1.82x and EV/EBITDA of 11.34x suggest a valuation that may be discounting the current growth and margin challenges. Historically, the stock's current trailing P/E of 17.97x is below its own historical range seen in recent quarters, which has fluctuated between approximately 12x and 50x, placing it near the lower end and suggesting the market has priced in significant pessimism, potentially creating a value opportunity if the company can execute a turnaround.
PE
18.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 12x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute and center on collapsing profitability. The Q4 net margin compression from 13.54% to 3.94% and the $250 million cost inflation headwind directly threaten earnings stability. While the balance sheet shows moderate leverage (Debt/Equity of 0.96) and solid TTM FCF of $1.5 billion, the sustainability of that cash flow is now in question if margin pressures persist. Revenue concentration is less of an issue due to geographic and segment diversification, but the negative 12.13% YoY growth in the latest quarter indicates top-line vulnerability.
Market & Competitive Risks are elevated by the stock's valuation compression. While the forward P/E of 11.29x appears cheap, it is contingent on an earnings recovery that may not materialize, creating a 'value trap' risk. The stock's beta of 0.868 indicates it has been less volatile than the market during its steep fall, suggesting this is a company-specific problem rather than a sector-wide issue, which could lead to prolonged underperformance. Competitive risks are highlighted by news of rivals like RadNet investing heavily in AI, potentially threatening GEHC's innovation edge in imaging and diagnostics.
Worst-Case Scenario involves a failure to stabilize margins combined with continued revenue declines, leading to consecutive earnings misses. This could trigger further analyst downgrades, a loss of investor confidence in the turnaround narrative, and a re-rating to a deeper discount. The realistic downside is to the 52-week low of $58.75, representing a -3.4% decline from current levels, or a more severe re-test of support levels established during the spin-off, potentially leading to a total drawdown matching the recent -32.53% max drawdown from the 52-week high.
FAQ
The key risks are, in order of severity: 1) Execution Risk: Failure to offset the $250M cost inflation, leading to further margin compression (Q4 net margin already fell 960 bps). 2) Revenue Risk: Continued decline in equipment sales, evidenced by the -12.13% YoY drop in Q4 revenue. 3) Valuation Trap Risk: The seemingly cheap forward P/E of 11.29x could expand if expected earnings fail to materialize. 4) Technical Risk: The stock is in a severe downtrend (-24.37% in 3 months) which can become self-reinforcing through negative sentiment.
The 12-month forecast is bifurcated. The base case (55% probability) sees a slow recovery with a target range of $65-$75, assuming margins partially recover and revenue stabilizes. The bull case (25% probability) targets $80-$89 on successful execution of cost controls. The bear case (20% probability) warns of a retest of the $58-$65 range if fundamentals worsen. The most likely outcome is the base case, hinging on the critical assumption that Q4 2025 represented the trough in profitability.
GEHC appears fairly valued to slightly undervalued based on a forward-looking basis, but this is entirely conditional. The trailing P/E of 17.97x reflects past profitability, while the forward P/E of 11.29x implies the market expects a substantial earnings recovery. Compared to its own historical P/E range, the stock is at the lower end. The valuation implies the market expects management to successfully navigate the $250 million cost inflation challenge. If they fail, the stock is overvalued; if they succeed, it is likely undervalued.
GEHC presents a high-risk, high-potential-reward situation. At a forward P/E of 11.29x and trading just 3.4% above its 52-week low, significant bad news is priced in. However, it is only a good buy for investors who believe the company's margin collapse is temporary and who have the patience for a potentially slow turnaround. The 25%+ upside to analyst bull-case targets is attractive, but it is counterbalanced by the real risk of further downside to the $58.75 support if execution falters. It is not a good buy for conservative investors.
GEHC is unsuitable for short-term investment due to its high volatility, negative momentum, and fundamental uncertainty. It is a candidate only for a long-term (3+ year) investment horizon, allowing time for the proposed operational turnaround to play out. The stock's low beta of 0.868 is misleading given its recent company-specific crash. Investors must be prepared for significant price swings and should use a dollar-cost averaging approach if building a position, with a minimum suggested holding period of 18-24 months to assess the recovery.